Cosmos Holdings Inc. Stock OTC Markets

Equities

COSM

US2214131078

Pharmaceuticals

Delayed OTC Markets 11:14:35 2021-10-05 am EDT 5-day change 1st Jan Change
4.51 USD -5.65% Intraday chart for Cosmos Holdings Inc. -2.45% -.--%
Sales 2023 * 51.29M Sales 2024 * 63.98M Capitalization 8.59M
Net income 2023 * -7M Net income 2024 * -8M EV / Sales 2023 * 0.17 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.13 x
P/E ratio 2023 *
-0.8 x
P/E ratio 2024 *
-1.09 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.51%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 58 16-02-25
Director of Finance/CFO 42 20-11-10
Chief Operating Officer 55 23-01-31
Members of the board TitleAgeSince
Director/Board Member 64 22-04-27
Director/Board Member 57 14-01-12
Chief Executive Officer 58 16-02-25
More insiders
Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.51 USD
Average target price
4 USD
Spread / Average Target
+684.31%
Consensus